Cite
A NOVEL CDK4/6 INHIBITOR WXJ-111, AGAINST BREAST CANCER THROUGH MEDIATED CELL-CYCLE ARREST AND APOPTOSIS.
MLA
Jing Ji, et al. “A Novel Cdk4/6 Inhibitor Wxj-111, against Breast Cancer through Mediated Cell-Cycle Arrest and Apoptosis.” Acta Poloniae Pharmaceutica, vol. 79, no. 3, May 2022, pp. 353–65. EBSCOhost, https://doi.org/10.32383/appdr/152215.
APA
Jing Ji, Jing Feng, Gang Pan, Ming-Xiao Lv, Jin-Yu Lv, Wen-Wen Liu, Xing-Bei He, Wen-Lian Tang, Qi-Lan Qian, Zhen Zhang, Yu-Xin Xu, Meng-Ru Xie, Dan-Dan Xia, Yu Bao, Xiu-Jun Wang, Jin-Ming Ma, & Bin Liu. (2022). A Novel Cdk4/6 Inhibitor Wxj-111, against Breast Cancer through Mediated Cell-Cycle Arrest and Apoptosis. Acta Poloniae Pharmaceutica, 79(3), 353–365. https://doi.org/10.32383/appdr/152215
Chicago
Jing Ji, Jing Feng, Gang Pan, Ming-Xiao Lv, Jin-Yu Lv, Wen-Wen Liu, Xing-Bei He, et al. 2022. “A Novel Cdk4/6 Inhibitor Wxj-111, against Breast Cancer through Mediated Cell-Cycle Arrest and Apoptosis.” Acta Poloniae Pharmaceutica 79 (3): 353–65. doi:10.32383/appdr/152215.